Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function

Br J Haematol. 2024 Jan;204(1):e11-e16. doi: 10.1111/bjh.19152. Epub 2023 Oct 11.

Authors

Omar Mamlouk¹, Paolo Strati², Lei Feng³, Ryan Sun³, Amy Ayers², Raphael E Steiner², Ranjit Nair², Christopher Flowers², Jeremy L Ramdial⁴, Neeraj Saini⁴, Samer A Srour⁴, Richard E Champlin⁴, Partow Kebriaei⁴, Loretta J Nastoupil², Maria A Rodriguez², Elizabeth J Shpall⁴, Yago Nieto⁴, Jason Westin², Sattva S Neelapu², Sreedhar Mandayam¹, Sairah Ahmed^{2

4}

Affiliations

¹ Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁴ Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 37822075
DOI: 10.1111/bjh.19152

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD19
Humans
Immunotherapy, Adoptive* / adverse effects
Kidney
Lymphoma* / therapy
T-Lymphocytes

Substances

Antigens, CD19